RFA offers option for ovarian cancer metastases in liver

Article

Radiofrequency ablation is effective for treating some liver metastases of ovarian cancer and could spare patients from repeated surgeries, according to a retrospective study from Massachusetts General Hospital.

Radiofrequency ablation is effective for treating some liver metastases of ovarian cancer and could spare patients from repeated surgeries, according to a retrospective study from Massachusetts General Hospital.

"Some studies have shown that patients with advanced ovarian cancer can survive longer if they have repeated surgery to remove recurrent or new disease," said lead author Dr. Debra Gervais. "We wanted to see if we could use RF ablation instead of repeated open surgical resection for some of these patients."

The study, published in the American Journal of Roentgenology in September, examined results for six patients with stage III and stage IV ovarian cancer that had metastasized to the liver.

The patients, who were treated consecutively over a six-year period at the Boston hospital, had six tumors: Five were solitary metastatic lesions, and one was a dominant liver mass in the small soft-tissue peritoneal nodule. Five tumors were along the periphery of the liver, and the sixth was intraparenchymal (stage IV). Mean tumor diameter was 2.7 cm.

Postablation, results were regularly assessed and monitored with contrast-enhanced CT and, in some cases, FDG-PET for up to 3.3 years.

The study concluded that one RFA treatment completely eliminated the tumor in five of six patients. Of the five patients who were treated successfully, one showed recurrence on FDG-PET scans nine months after treatment and required a second ablation procedure, which was successful.

Although the treatment was successful in five cases, new tumors developed apart from the target site, and patients required other treatments such as surgery and chemotherapy.

The authors concluded there is a role for RFA in some cases to achieve local control.

For more information from the Diagnostic Imaging archives:

RFA and cryoablation expand treatment of hepatic tumors

False positives foil hopes for ovarian cancer screening

Genetic findings affect diagnosis, treatment of ovarian cancer

FDG-PET predicts ovarian cancer response to chemotherapy

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.